Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-1387 combined with chemotherapy in advanced pancreatic cancer
CTR20202368Phase 2Terminated
- Sponsor
- Ascentage Pharma
- Start
- Mar 2021
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dasminapant in pancreatic cancer (PC), sponsored by Ascentage Pharma. Started Mar 2021; status: terminated.
02
Drugs
dasminapant
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20202368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202368.